Find public news by keyword, exact ticker, category and date.
Open a ticker page for its news coverage. The news search below stays a text search.
2 results loaded, newest first. End of these results.
CLNN is advancing an oral nanotherapeutic for ALS, citing consistent neurofilament reduction and survival benefits in trials. The company says an NDA submission is imminent, with a confirmatory Phase III and targeted commercialization planned.
CLNN says an ALS nanotherapeutic is nearing NDA submission after clinical survival and neurofilament light benefits, with a strong safety profile. Regulatory review is expected to begin soon, with commercialization targeted next year.